On February 1, 2019, the Board of Directors of Proteostasis Therapeutics, Inc. elected Kimberlee Cobleigh Drapkin as a Class III director whose term will expire at the Company's 2021 annual meeting of shareholders, effective immediately. Ms. Drapkin has also been appointed to the Audit Committee as its Chairperson and to the Compensation Committee. On February 5, 2019, the Board elected Emmanuel Dulac as a Class III director whose term will expire at the Company's 2021 annual meeting of shareholders, effective immediately. Ms. Drapkin, age 50, has served as the chief financial officer of Jounce Therapeutics, Inc. since August 2015, and treasurer since February 2013. Dr. Dulac, age 49, has served as Chief Commercial Officer and Chief International Strategy at Alnylam Pharmaceuticals since August 2016.